J Asthma Allergy Clin Immunol.
1998 Sep;18(3):466-472.
Serum eosinophil cationic protein in patient with bronchial asthma ;
comparison with other markers of disease activity
Abstract
-
BACKGROUND: Serum eosinophil cationic protein(ECP) level has been proposed as a indirect
marker of eosinophilic inflammation of the airway in bronchial asthma.
OBJECTIVE
To evaluate serum ECP against indirect clinical markers of disease, we
compared bronchial obstruction, bronchial hyperresponsiveness and peripheral blood
eosinophil counts, total IgE with serum ECP levels in patients with bronchial asthma and
normal controls.
METHOD: Fourty-two patients with bronchial asthma and twenty-six normal controls were
enrolled. Measurement were made by spirometry, inhalation challenge with methacholine,
peripheral blood eosinophil counts, total IgE and FEIA(fluoroenzymatic immunoassay) of
serum ECP
RESULT: Serum ECP levels were significantly higher in asthmatic patients than normal
controls(p<0.0,5). Serum ECP levels were correlated with peripheral blood eosinophil
counts(p<0.01, r=0.544) and bronchial hyperresponsiveness(PC,)(p<0.01, r=-0.456) in
patients with bronchial asthma. Serum ECP levels were correlated with degree of bronchial
obstruction(FEV, % to predicted value, FEV1/FVC%) in total subjects, but not in asthmatic
patients.
CONCLUSION
Serum ECP level may be used as indicator of disease activity in
bronchial asthma and be helpful in differentiation between normal person and asthmatic
patients on simple serological method. Further studies on the changes of serum ECP
levels according to disease course and therapeutic responses are needed.